A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with FM

The objective of this study was to evaluate the relative efficacy
and tolerability of subcutaneously (s.c.) administered salmon
calcitonin (sCT) in the treatment of patients with
fibromyalgia. Eleven patients who fulfilled the American
College of Rheumatology classification criteria for
fibromyalgia were studied in a double-blind, crossover trial
in which they alternatively received salmon calcitonin (100 IU
s.c.) and isotonic saline (1 cc s.c.) for four weeks, with a
four weeks wash-out period between the treatments. None of the
11 outcomes measures (seven analog scales, dolorimetry score,
and three SIP scores) showed a significant improvement with
sCT. The principal side effect observed with sCT was nausea in
ten patients and erythema in four patients. These data suggest
that sCT given at a dose of 100 IU daily for one month is not
effective in the treatment of fibromyalgia.

1 Star2 Stars3 Stars4 Stars5 Stars (15 votes, average: 3.15 out of 5)

Leave a Reply